Arrowhead Pharmaceuticals ARWR
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 73rd percentile, 5-year average -269.1x
Near the top of its 5-year range · 100th percentile, 5-year average 13.4x
#5306 of 5331 stocks by PB (1 = cheapest)
Around its usual level · 50th percentile, 5-year average 94.6x
#4649 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 134.21 | – | 13.44 | 100% (pricier than usual) | #5306 of 5331 (1 = cheapest) |
| PE | -9.35 | -8.40 | -269.07 | 73% (pricier than usual) | – |
| PS | 14.98 | 22.03 | 94.60 | 50% (cheaper than usual) | #4649 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ARWR.
Sign in to join the discussion.